Table 2.

Treatment characteristics and outcome of the patients included in this series

Variable	Patients (n = 99, %)	Initial treatment
		Local treatment (n = 60, 60.6%)	Observation/medical treatment (n = 39, 39.4%)
Biopsy
Core needle biopsy	70, 70.7%	38, 63.3%	32, 82.1%
Open biopsy	29, 29.3%	22, 36.7%	7, 17.9%
Total number of surgeries
Median	1	1	0
IQR	0–1	1–2	0–0
NSAIDs
No	82, 82.8%	60, 100.0%	22, 56.4%
Yes	17, 17.2%	0	17, 43.6%
Tyrosine kinase inhibitor
No	98, 99.0%	60, 100.0%	38, 97.4%
Yes	1, 1.0%	0	1, 2.6%
Anti-hormonal therapy + NSAIDs
No	87, 87.9%	59, 98.3%	28, 71.8%
Yes	12, 12.1%	1, 1.7%	11, 28.2%
Low-dose chemotherapy
No	72, 72.7%	56, 93.3%	16, 41.0%
Yes	27, 27.3%	4, 6.7%	23, 59.0%
Follow up period (months)
Median	57	58.5	55
IQR	33–86	35–96	27–85
Event
No	71, 71.7%	41, 68.3%	30, 76.9%
Yes	28, 28.3%	19, 31.7%	9, 23.1%
Interval between the diagnosis and event
Median	18	19	13
IQR	9–32	9–36	9–24
MSTS score
Median	26	29	21
IQR	21–30	23–30	19–29.5

IQR interquartile range, NSAIDs non-steroidal anti-inflammatory drugs, MSTS Musculoskeletal Tumor Society